CRM
RPRX icon

Cramer Rosenthal McGlynn’s Royalty Pharma RPRX Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100,000
Closed -$4.86M – 103
2020
Q2 		$4.86M Buy
+100,000
New +$4.95M 0.2% 86

Other funds holding RPRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cramer Rosenthal McGlynn's RPRX Position: Q3 2020 in Review

Cramer Rosenthal McGlynn sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 100,000 shares — an estimated $4.86M sold.

Cramer Rosenthal McGlynn first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $4.86M in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

  • Cramer Rosenthal McGlynn reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 100,000 Royalty Pharma shares in Q3 2020, an estimated $4.86M.
  • Cramer Rosenthal McGlynn first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
  • Cramer Rosenthal McGlynn's Royalty Pharma position peaked at $4.86M in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2020, filed 13 Nov 2020.